Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mara Habash, Hannah Guiang, Irvin Mayers, Anna Quinton, Vivian Vuong, Aidan Dineen, Sumeet Singh, Danny Gibson & Adrian P. Turner. (2023) Cost-effectiveness of tezepelumab in Canada for severe asthma. Journal of Medical Economics 26:1, pages 902-914.
Read now
Read now
Ivo Abraham, Kenneth K. C. Lee & Mike Gregg. (2023) Journal of Medical Economics in review: high impact articles from 2022. Journal of Medical Economics 26:1, pages 303-307.
Read now
Read now
Masaharu Shinkai & Tadataka Yabuta. (2023) Tezepelumab: An Anti-Thymic Stromal Lymphopoietin Monoclonal Antibody for the Treatment of Asthma. Immunotherapy 15:17, pages 1435-1447.
Read now
Read now
Maria Gabriella Matera, Josuel Ora, Paola Rogliani & Mario Cazzola. (2023) An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. Expert Opinion on Drug Discovery 18:9, pages 951-963.
Read now
Read now
Articles from other publishers (17)
Ekaterini Tiligada, Daria Gafarov, Maria Zaimi, Joana Vitte & Francesca Levi-Schaffer. (2024) Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases. Annual Review of Pharmacology and Toxicology 64:1, pages 481-506.
Crossref
Crossref
Alfredo de Diego Damia & Ana María Martinez Valle. (2024) Antialarmins in Severe Asthma. Archivos de Bronconeumología 60:1, pages 5-6.
Crossref
Crossref
Bérengère Macabeo, Théophile Rotrou, Aurélie Millier, Clément François & Philippe Laramée. (2023) The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain. PharmacoEconomics - Open 8:1, pages 5-18.
Crossref
Crossref
Marco Caminati, Roland Buhl, Jonathan Corren, Nicola A. Hanania, Harold Kim, Stephanie Korn, Marek Lommatzsch, Neil Martin, Andrea Matucci, Shuaib M. Nasser, Ian D. Pavord & Christian Domingo. (2023) Tezepelumab in patients with allergic and eosinophilic asthma. Allergy.
Crossref
Crossref
Gabriel Lavoie & Ian D. Pavord. (2023) Which biologic? New findings from a real‐world study. Respirology 28:12, pages 1091-1092.
Crossref
Crossref
Yahiya Y. Syed. (2023) Tezepelumab in severe asthma: a profile of its use. Drugs & Therapy Perspectives 39:12, pages 393-403.
Crossref
Crossref
V. V. Naumova, Е. К. Beltyukov, О. P. Kovtun, G. А. Bykova, О. G. Smolenskaya, A. A. Shtanova & D. A. Stepina. (2023) Direct comparative study of the effectiveness of mepolizumab and dupilumab in patients with severe non-allergic eosinophilic asthma. Meditsinskiy sovet = Medical Council.
Crossref
Crossref
Andrew Menzies-Gow, Christopher S. Ambrose, Gene Colice, Gillian Hunter, Bill Cook, Nestor A. Molfino, Jean-Pierre Llanos & Elliot Israel. (2023) Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study. Advances in Therapy 40:11, pages 4957-4971.
Crossref
Crossref
Andreas Freitag, Laura Gurskyte & Grammati Sarri. (2023) Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations. Journal of Comparative Effectiveness Research 12:10.
Crossref
Crossref
Gabriel Cavalcante Lima Chagas, Débora Xavier, Lorena Gomes, Juliana Ferri-Guerra & Rafael Enrique Hernandez Oquet. (2023) Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis. Current Allergy and Asthma Reports 23:6, pages 287-298.
Crossref
Crossref
Tyler Pitre, Tanvir Jassal, Albi Angjeli, Vineeth Jarabana, Sricherry Nannapaneni, Ayesha Umair, Muizz Hussain, Gareth Leung, Sarah Kirsh, Johnny Su, Kairavi Desai, Jade Coyne, Sindu Mohan & Dena Zeraatkar. (2023) A comparison of the effectiveness of biologic therapies for asthma. Annals of Allergy, Asthma & Immunology 130:5, pages 595-606.
Crossref
Crossref
Tanawin Nopsopon, Grace Lassiter, Ming-Li Chen, G. Caleb Alexander, Corinne Keet, Hwanhee Hong & Ayobami Akenroye. (2023) Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. Journal of Allergy and Clinical Immunology 151:3, pages 747-755.
Crossref
Crossref
Mona Al-Ahmad, Asmaa Ali & Ahmed Maher. (2023) Omalizumab Transitions in Severe Asthma: Factors Influencing Switching Decisions and Timing for Optimal Response. Medical Principles and Practice 32:6, pages 323-331.
Crossref
Crossref
Pooja Roy, Zahin Islam Rafa, Sharar Naiarin Haque, Tasniem Tasha, Soumyadipto B Arko, Harshita Agrawal, Md Ibrahim Razu, Anusha Parisapogu, Sadia Maisha, Mohammad A Siddique, Farhana Karim Abbasi, Nishat Shama, Supti Dev Nath, Ammy S Ghosh & Fahmina Quader. (2022) The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials. Cureus.
Crossref
Crossref
Stefano Piazza, Marco Fumagalli, Giulia Martinelli, Carola Pozzoli, Nicole Maranta, Marco Angarano, Enrico Sangiovanni & Mario Dell’Agli. (2022) Hydrolyzable Tannins in the Management of Th1, Th2 and Th17 Inflammatory-Related Diseases. Molecules 27:21, pages 7593.
Crossref
Crossref
Adrian Gillissen. (2022) Wichtige Updates zu Asthma, Sinusitis und Pneumonie. MMW - Fortschritte der Medizin 164:19, pages 5-5.
Crossref
Crossref
Christine Willen. (2022) Nationale VersorgungsLeitlinie: Biologika wichtige Option bei schwerem Asthma. Deutsches Ärzteblatt Online.
Crossref
Crossref